Story
FDA Stands By Taylor Farms Probe Despite Retracted Cyclospora Test

The U.S. Food and Drug Administration is defending its investigation into a widespread cyclosporiasis outbreak linked to Taylor Farms lettuce, stating its case remains strong despite retracting an initial positive test result. The outbreak has sickened over 1,600 people nationally and has been connected to Yum Brands' (NYSE:YUM) Taco Bell locations.
Investigation Continues Amid Test Retraction
The FDA said Monday that the epidemiological and traceback evidence linking lettuce from Taylor Farms de Mexico to the outbreak remains unchanged. The statement came after the agency first announced a positive test for the cyclospora parasite on a border sample Saturday, only to call it a "false positive" on Sunday following a quality-control review.
Acting FDA Commissioner Kyle Diamantas defended the decision to publicize the initial result, citing the urgency of an outbreak with more than 1,600 cases and ongoing illnesses. "We found it was important to share this actionable public health information," said Acting Deputy Commissioner for Food Donald Prater on a call with reporters.
Outbreak Scope and Restaurant Impact
Cyclosporiasis is an intestinal infection contracted from consuming food or water contaminated with feces. The current outbreak has led to significant public health responses and has impacted consumer behavior.
Ad- In Michigan, health officials reported 6,148 cases linked to the outbreak as of Monday, an increase of 1,146 since Friday.
- The state has recorded 102 hospitalizations, with no deaths reported.
- According to data from Placer.ai, consumer foot traffic at Taco Bell fell 30.9% on Friday compared to its recent day-of-week average. Traffic at Chipotle (NYSE:CMG) and Cava (NYSE:CAVA) was down 6.9% and 4.2%, respectively.
Focus Remains on Epidemiological Evidence
Experts noted that the retracted lab result does not invalidate the broader investigation. Former FDA Commissioner Scott Gottlieb said Monday that the agency's conclusions rely primarily on epidemiological evidence rather than a single test on a recent sample.
"This isn’t the product that was affected - it went into the supply chain three weeks ago," Gottlieb said, explaining that the traceback investigation stands on its own. The FDA confirmed the border test was separate from the main U.S. outbreak investigation.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.